Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Akeso, Inc. ( (HK:9926) ).
Akeso, Inc. has scheduled a board meeting for March 26, 2026 to review and approve the annual results for the financial year ended December 31, 2025, and to authorize their publication. The timing signals the company is moving toward its regular reporting cycle, an event that will be closely watched by investors and other stakeholders for insights into operational performance and strategic direction over the past year.
The meeting will also allow the board to address any other business, providing a formal setting to consider additional corporate matters alongside the results. The announcement underscores the company’s adherence to Hong Kong listing requirements on timely disclosure, and may shape market expectations ahead of the release of Akeso’s audited financial and operating metrics for 2025.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
More about Akeso, Inc.
Akeso, Inc. is a Cayman Islands–incorporated company listed in Hong Kong, operating in the biopharmaceutical sector. The firm is led by chairwoman and executive director Dr. Xia Yu alongside a board comprising executive, non-executive, and independent non-executive directors, reflecting a typical Hong Kong–listed corporate governance structure focused on R&D-driven healthcare growth.
Average Trading Volume: 6,022,108
Technical Sentiment Signal: Buy
Current Market Cap: HK$101.5B
See more insights into 9926 stock on TipRanks’ Stock Analysis page.